Pathologic Re-Review Of TURBT Specimens By GU Pathologist Changes NMIBC Risk Stratification For More Than 20% Of Patients, Study Finds

Renal & Urology News (6/27, Charnow) reports, “Pathologic re-review of transurethral resection of bladder tumor (TURBT) specimens by a dedicated genitourinary (GU) pathologist led to a change in risk stratification for more than one-fifth of patients with nonmuscle-invasive bladder cancer (NMIBC), investigators reported” in Urologic Oncology: Seminars and Original Investigations. Overall, “results showed that 21% of patients with less than cT2 disease experienced a change in American Urological Association risk stratification: 13% with an increase and 8% with a decrease.”